Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether coadministration of ezetimibe 10 mg/day with
simvastatin 20 mg/day for 12 weeks will result in greater reduction of LDL-C, total
cholesterol (TC), triglycerides (TG), non HDL-C, and apolipoprotein B (ApoB), and greater
increase in HDL-C, compared with simvastatin 20 mg/day as monotherapy for 12 weeks in
African-American subjects with primary hypercholesterolemia. This study is being performed to
better define the efficacy of ezetimibe coadministered with simvastatin in this population.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin